Myriad Genetics, Inc. (MYGN) Fair Value 2026

MYGN · In Vitro & In Vivo Diagnostic Substances ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, Myriad Genetics, Inc. (MYGN) trades at $6.31, approximately 1934% above CirclFi’s Bayesian DCF fair value of $0.31. QOC: 5.9/10. Value Trap Risk: 24/100 (SAFE). 12/13 models active.

Key Facts

Ticker
MYGN
Price
$6.31
Quality Score
5.9/10
Value Trap Risk
24/100
Models Active
12/13
Last Updated
Strength: Earnings Power Value suggests +229.1% upside with 25% confidence
Risk: Limited model coverage (12/13) may reduce confidence

Is Myriad Genetics, Inc. (MYGN) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, Myriad Genetics, Inc. (MYGN) appears overvalued as of : the median of 12 independent fair value estimates is $5.33, 15.5% below the current price of $6.31. Estimates range from $0.31 to $20.77. MYGN scores 5.9/10 on fundamental quality and 24/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Myriad Genetics, Inc. Stock in 2026? →

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($6.31)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.31 -95.1%
Earnings Power Value
Medium Conviction
 $20.77 +229.1%
CUCE Ensemble
Low Conviction
 $7.90 +25.3%
First Chicago
High Conviction
 $5.81 -8.0%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Myriad Genetics, Inc. (MYGN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Myriad Genetics, Inc. at its current price of $6.31. The composite intrinsic value is estimated at $8.16 (+29.4% average return), with 7 models flagging overvaluation risk. The most optimistic model, EPV, places fair value at $20.77 (+229.1%), while Bayesian DCF — the most conservative — estimates $0.31 (-95.1%). This +324.2% gap reflects genuine analytical uncertainty about Myriad Genetics, Inc.'s intrinsic worth.

What Do the Models Say About MYGN?

12 of 13 models are currently active for MYGN. Of these, 5 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates MYGN's intrinsic value at $0.31, implying -95.1% downside from the current price. See which stocks rank higher →

How Does MYGN Rank in In Vitro & In Vivo Diagnostic Substances?

Among 17 In Vitro & In Vivo Diagnostic Substances stocks, MYGN ranks #10 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

Myriad Genetics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is MYGN a Value Trap?

CirclFi's Value Trap algorithm assigns MYGN a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Myriad Genetics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Myriad Genetics, Inc.'s fundamental quality profile registers 5.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +324.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MYGN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MYGN's 12 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Myriad Genetics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar In Vitro & In Vivo Diagnostic Substances Stocks Should You Also Analyze?

8 related In Vitro & In Vivo Diagnostic Substances stocks with 13-model coverage

IDXXIDEXX Laboratories, Inc.QOC 10.0LNTHLantheus Holdings, Inc.QOC 10.0NEOGNeogen CorporationQOC 7.6ICCCImmuCell CorporationQOC 7.2QDELQuidelOrtho CorporationQOC 6.9NTLAIntellia Therapeutics, Inc.QOC 6.2CLDXCelldex Therapeutics, Inc.QOC 6.1VNRXVolitionRX LimitedQOC 6.1

Read investment analysis: IDXX · LNTH · NEOG · ICCC · QDEL

Frequently Asked Questions About Myriad Genetics, Inc.

What is Myriad Genetics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Myriad Genetics, Inc. (MYGN) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.31. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MYGN overvalued or undervalued right now?

At $6.31, 5 of 12 active models suggest MYGN may be undervalued, while 7 indicate potential overvaluation. The median of all 12 fair value estimates is $5.33, 15.5% below the current price of $6.31 — a consensus view that MYGN is overvalued. The assessment depends on which methodology best fits Myriad Genetics, Inc.'s business model in In Vitro & In Vivo Diagnostic Substances.

What does a Quality of Company score of 5.9 mean for MYGN?

Myriad Genetics, Inc.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on MYGN?

CirclFi analyzes MYGN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is MYGN a value trap in 2026?

Myriad Genetics, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 12-model valuation engine, Myriad Genetics, Inc. (MYGN) has a median fair value of $5.33 — 15.5% below the current price of $6.31 — as of 2026-07-15.” Source: circlfi.com/stock/MYGN/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on MYGN.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access